PBAC's latest decision on Mometasone furoate with indacaterol: Recommended with restriction (2020). Considered for Maintenance treatment of asthma in patients aged 12 years and older who have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2020
Submissions
1
2020 → 2020
Eligible population
Adults and adolescents aged 12 years and older with asthma not adequately controlled with inhaled corticosteroids and 'as needed' short-acting beta2-agonists, or not adequately controlled with long-acting beta2-agonists and low dose inhaled corticosteroids.